Blueprint Medicines Corporation (NASDAQ:BPMC) Position Trimmed by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC decreased its position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 2.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 135,909 shares of the biotechnology company's stock after selling 3,834 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.21% of Blueprint Medicines worth $12,029,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Blueprint Medicines by 53.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 4,957 shares of the biotechnology company's stock valued at $426,000 after acquiring an additional 1,735 shares during the period. Cerity Partners LLC acquired a new position in shares of Blueprint Medicines during the fourth quarter valued at $291,000. SG Americas Securities LLC boosted its holdings in shares of Blueprint Medicines by 70.1% during the first quarter. SG Americas Securities LLC now owns 7,276 shares of the biotechnology company's stock valued at $644,000 after acquiring an additional 2,999 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Blueprint Medicines by 4.7% during the first quarter. Fifth Third Bancorp now owns 3,221 shares of the biotechnology company's stock valued at $285,000 after acquiring an additional 146 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Blueprint Medicines by 31.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,650 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 399 shares during the period.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded up $0.20 during midday trading on Friday, hitting $129.48. The company's stock had a trading volume of 2,980,900 shares, compared to its average volume of 1,532,595. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 1.01. The stock's 50-day moving average price is $119.38 and its 200-day moving average price is $102.84. Blueprint Medicines Corporation has a 12 month low of $73.04 and a 12 month high of $129.65. The company has a market capitalization of $8.36 billion, a PE ratio of -52.42 and a beta of 0.89.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative return on equity of 64.60% and a negative net margin of 27.70%. Blueprint Medicines's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.40 EPS. Analysts anticipate that Blueprint Medicines Corporation will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $100.51, for a total transaction of $228,559.74. Following the sale, the chief operating officer owned 64,718 shares in the company, valued at approximately $6,504,806.18. The trade was a 3.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ariel Hurley sold 2,752 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $103.13, for a total value of $283,813.76. Following the sale, the insider owned 16,944 shares in the company, valued at approximately $1,747,434.72. The trade was a 13.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,351 shares of company stock worth $1,384,244 in the last quarter. 4.21% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BPMC. Wall Street Zen upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. JMP Securities restated a "market perform" rating on shares of Blueprint Medicines in a research note on Tuesday, June 3rd. Wolfe Research cut shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. restated a "neutral" rating and set a $129.00 price objective (down from $130.00) on shares of Blueprint Medicines in a research note on Monday, June 2nd. Finally, Cowen cut shares of Blueprint Medicines to a "hold" rating in a research note on Monday, June 2nd. Eighteen research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $128.25.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.